Dr Beatrice Seddon is a highly experienced consultant specialising in the treatment of bone and soft tissue sarcomas. With 20 years of dedicated service, she has made significant contributions to the field of oncology. Dr Seddon was a key member of the Sarcoma Unit at University College Hospital until 2022, where she treated patients using advanced chemotherapy and radiotherapy techniques, including proton beam therapy, which is available to private patients through Proton International London.

Dr Seddon received her specialised training in sarcoma treatment at the prestigious Royal Marsden and Middlesex Hospitals in London. Her expertise lies exclusively in the management of soft tissue and bone sarcomas, utilising both chemotherapy and radiotherapy to provide comprehensive care.

In addition to her clinical practice, Dr Seddon completed her PhD at the Institute of Cancer Research, focusing on the imaging of tumour hypoxia. She has a profound interest in clinical trials related to sarcoma and has served as principal and chief investigator for numerous national and international studies on sarcoma chemotherapy and radiotherapy. Her commitment to advancing sarcoma research is evident through her active involvement in the NCRN Sarcoma Clinical Studies Group, the NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad), and the EORTC Soft Tissue and Bone Sarcoma Group.

Dr Seddon is also a dedicated educator, regularly teaching and lecturing on the management of sarcomas. Her areas of expertise include the treatment of soft tissue sarcomas, bone sarcomas, gastrointestinal stromal sarcoma, and gynaecological sarcomas such as leiomyosarcoma, endometrial stromal sarcoma, and PEComa. She is proficient in administering chemotherapy and various forms of radiotherapy, including intensity modulated radiotherapy (IMRT) and proton beam therapy (PBT).

Dr Beatrice Seddon’s extensive experience, combined with her commitment to research and education, makes her a leading figure in the field of sarcoma treatment. She continues to provide exceptional care to her patients while contributing to the advancement of oncology through her research and teaching efforts.